Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug development company headquartered in Utah focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. The company was founded in 2002 with the mission to bring its new class of opioid pain therapies and addiction treatment alternatives to the healthcare community.
We believe strongly in the value to humanity of a class of potent analgesics with the potential to relieve pain and suffering without the problems of abuse and addiction, serious side effects and death from overdose.
The Company believes that superior shareholder and investor return can be accomplished while delivering relief to millions of pain sufferers and opiate addicts.
The Company has sought to advance its technology in a prudent and cost-effective fashion and has benefited from visionary investors and from collaborative researchers and scientists as well as from U.S. government research funding.
Phoenix PharmaLabs welcomes your support and assistance in the common goal of solving one of the world's most vexing and pervasive problems. Please contact us for additional information.
Phoenix PharmaLabs Releases New Data Confirming That Their <...
Novel Pinkiller with Little or No Signs of Addiction and Other Serious Opioid Side Effects Patented by Phoenix PharmaLabs